Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher, DiaSorin, VolitionRx, and BioAffinity

NEW YORK (360Dx) – Thermo Fisher Scientific said this week that it acquired Core Informatics, which provides a cloud-based platform that supports scientific data management. Thermo Fisher noted that Core's services will enhance its existing informatics solutions and complement its cloud platform, which supports the company's genetic analysis, qPCR, and proteomics systems.

Core's capabilities include laboratory information management systems, electronic laboratory notebook technologies, and scientific data management solutions, Thermo Fisher said.

Terms of the acquisition were not disclosed.

Italy-based DiaSorin said that its 2016 revenues grew 14 percent to €569.3 million ($609.2 million), up from €499.2 million in 2015. Revenues for Focus Diagnostics, whose immunodiagnostic and molecular diagnostic products business DiaSorin purchased from Quest Diagnostics for $297.8 million in May 2016, was €44.4 million, DiaSorin said.

The firm posted a net profit of €112.6 million, up 12 percent, from €100.5 million in 2015. DiaSorin said it expects that 2017 revenues will grow by 11 percent over 2016's figure.

Belgium-based VolitionRx said that it had a net loss of $11.9 million, or $0.52 per share, for the year ended Dec. 31 2016, compared to a loss of $9.5 million, or $0.54 per share, in 2015.

The firm noted that in 2016, it received CE marking on its Nu.Q colorectal cancer screening triage test and several Nu.Q biomarker assays, allowing their clinical use in the 28 European Union countries.

VolitionRx said it raised $24.9 million through public offerings in 2016.

The firm's cash and cash equivalents at the end of 2016 was $21.7 million.

The San Antonio City Council has authorized the San Antonio Economic Development Corporation to invest in BioAffinity Technologies, a local biotech company focused on the need for non-invasive, early-stage cancer diagnostics and improved cancer treatments, BioAffinity said this week. An economic development agreement requires BioAffinity to accelerate job creation and remain in San Antonio as it develops and commercializes diagnostic tests and targeted cancer therapeutics, the firm said.   

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.